Anticipated reactions to learning Alzheimer's disease biomarker results

Alzheimers Res Ther. 2022 Jun 22;14(1):85. doi: 10.1186/s13195-022-01027-2.

Abstract

Introduction: We developed the Alzheimer's Biomarker Survey to assess willingness to enroll in biomarker studies that disclose results and anticipated reactions to an elevated biomarker result.

Methods: Participants included cognitively unimpaired adults enrolled in longitudinal AD studies (n = 334, mean age = 64.8 ± 7.7, 44% non-Hispanic Black or African American). Exploratory and confirmatory factor analyses determined the latent structure comprising anticipated reactions to learning AD biomarker results. Measurement invariance was tested across racial groups.

Results: Two models comprising behavior change and psychological impact fit well for the total sample and the two racial groups. The 2-factor behavior change model assessed constructs of planning and dementia risk-reduction. The 3-factor psychological impact model assessed constructs of distress, cognitive symptoms, and stigma. Both models exhibited measurement invariance across racial groups.

Discussion: The 28-item Anticipated Reactions to AD Biomarker Disclosure scale is a reliable and valid measure of anticipated reactions when communicating AD biomarker results to research participants.

Keywords: Biomarker disclosure; Preclinical Alzheimer’s disease; Psychometrics; Psychosocial; Risk communication.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / psychology
  • Biomarkers
  • Factor Analysis, Statistical
  • Humans
  • Longitudinal Studies
  • Middle Aged
  • Surveys and Questionnaires

Substances

  • Biomarkers